Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | CORALLEEN: kicking chemo?

Aleix Prat • 14 May 2020
ESMO Breast 2020
Breast Cancer Letrozole Ribociclib
CORALLEEN

Aleix Prat, MD, PhD, Clinical and Provincial Hospital of Barcelona, Barcelona, Spain, discusses the CORALLEEN trial (NCT03248427), which investigated neadjuvant multi-agent chemotherapy or letrozole plus ribociclib in luminal B/HER2-negative breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Aleix Prat

3:18
Molecular heterogeneity in HER2+ breast cancer and predicting outcomes
Aleix Prat • 7 Dec 2021
6:15
Beyond HER2: dissecting tumor heterogeneity
Aleix Prat • 14 May 2020
2:49
HER2-E pCR with anti-HER2-based neoadjuvant therapies
Aleix Prat • 18 May 2020
3:22
HER2 blockade in HER2-E induces low-proliferative luminal A phenotype
Aleix Prat • 14 May 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals